Belrose Pharma develops specialty pharmaceuticals with improved clinical profiles designed to treat a broad range of conditions with a focus on rare diseases with high unmet medical need. Belrose is advancing development of an undisclosed portfolio of promising clinical stage product candidates.
- Early stage candidates (with or without preclinical data)
- Candidates that have completed Phase 1 and/or Phase 2b (dose ranging) studies
- Candidates that have complete Phase 2/3 clinical trials but have failed to meet their primary endpoint and/or have run into other development challenges
Belrose is deploying its proprietary “releasable linker” conjugation technology and other techniques to improve the clinical efficacy of both novel therapeutics and approved molecules that would benefit from improved PK profile, increased bioavailability and more convenient administration.
Belrose is also developing several other Preclinical Development Candidates involving small molecules, peptides, and biologic drug candidates, including programs involving a combination of drugs using our proprietary linker technologies. These drug candidates, including programs in enzyme replacement therapies, diabetes, and oncology, are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, or tissue targeting of the original native drugs, and thus improve the overall benefits and use of a drug to patients.
Please see product-specific information and feel free to contact us for additional details.